MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG. by Rodrigo Ibarra-García-Padilla (19697623)

AR1’s occurrence gives rise to a decreased preference of ABP for AR2 and 3. by Li-Dong Huang (5659273)

Decreased neuronal cells with increased astrocytes in HIV-1 Tg rats. by Young-Eun Cho (325567)

Novel chromobox 2 inhibitory peptide decreases tumor progression by Lindsay W. Brubaker (15099942)

LAMP1 decreased within MoDCs infected with <i>P. gingivalis</i> expressing Mfa1. by Ahmed R. El-Awady (697683)

Automated wound healing assay showing decreased motility of IL-4 treated HCAEC. by Tom Skaria (2733439)

Decreased cell stiffness after dissociation of intercellular adhesion. by Kristina Seiffert-Sinha (627059)

“…Cell stiffness was measured before and after the nanorobotic surgery and decreases from 30.0±1.5 kPa to 20.5±2.8 kPa, respectively. …”

RNA interference-mediated decrease in Ixofin3D results in decreased <i>B. burgdorferi</i> burden in the salivary glands and in murine skin. by Sukanya Narasimhan (73432)

(A) Decreasing CaMKII activity by KN-93 (high-3 µmol/L, low-0.5 µmol/L), AIP (high-10 µmol/L, low-2 µmol/L), or decreasing calmodulin activity by W-7 (high-50 µmol/L, low-20 µmol/L) decreases spontaneous AP firing rate (n = 10 for each drug), cAMP (n = 4 for each drug) and ATP (n = 5 for each drug). by Yael Yaniv (162548)

Subjects:

(R)-albuterol decreases cytokine mRNA levels in activated T cells by Marcela A Ferrada (41716)

“…</p><p></p> (R)-albuterol, (S)-albuterol or racemic albuterol (R + S) at a dose (10M) were added to T (EL-4) cells pre-activated with mitogens Concanavalin A (Con A, 5 μg/ml) and phorbol myristate acetate (PMA, 100 ng/ml) (CP). …”

Deletion of <i>sagA</i> alone results in a decrease in nasopharyngeal infection. by Blake A. Shannon (14197601)

PTH decreased cell apoptosis in a Flt-3L expanded population. by Flavia Q. Pirih (360515)

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects: